A Phase 1 Study of Allogeneic Natural Killer Cell Therapy in Glioma Patients
Recruiting Phase 2 NCT06687681
Study Description
Evaluating the Safety and Effectiveness of Injecting Donor Natural Killer Cells in Patients with Brain Tumors (Gliomas)
Study Details
- Registry ID:
- NCT06687681
- Conditions:
- Glioma Glioblastoma Multiforme, High Grade Glioma (III or IV)
- Phase:
- Phase 2
- Target Enrollment:
- 40 participants
- Start Date:
- Age Range:
- 3–70 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Rasoul Akram hospital
Tehran, Iran, Islamic Republic of
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.